FATE
NASDAQFate Therapeutics Inc.
Price$2.14+0.03 (+1.42%)
01:30 PM07:45 PM
News · 26 weeks63+6%
2025-12-282026-06-21
Mix4690d
- Other21(46%)
- Insider17(37%)
- SEC Filings6(13%)
- Analyst1(2%)
- Leadership1(2%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Redmile Group, Llc4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
- INSIDERSEC Form 4 filed by Director Lee Michael Stewart4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
- INSIDERSEC Form 4 filed by Director Xu Yuan4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
- INSIDERSEC Form 4 filed by Director Jooss Karin4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
- INSIDERSEC Form 4 filed by Director Epstein Robert S4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
- INSIDERSEC Form 4 filed by Director Agarwal Shefali4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
- INSIDERSEC Form 4 filed by Director Abernethy Matt4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
- INSIDERSEC Form 4 filed by Director Rastetter William H4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
- INSIDERSEC Form 4 filed by Director Hamill Laura4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hamill Laura3 - FATE THERAPEUTICS INC (0001434316) (Issuer)
- SECFate Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - FATE THERAPEUTICS INC (0001434316) (Filer)
- PRFate Therapeutics Appoints Laura Hamill to Board of DirectorsSAN DIEGO, June 15, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune diseases, today announced the appointment of Laura Hamill to its Board of Directors. Ms. Hamill is a global senior executive with more than three decades of commercial and strategic management experience across the biopharmaceutical industry. "We are delighted to welcome Laura to our Board of Directors," said Bob Valamehr, Ph.D., MBA, President and Chief Executive Officer of Fate Therapeutics. "Laur
- PRAfter CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune CellIssued on behalf of GT Biopharma, Inc. Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else. SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. But T-cell therapies also carry hard limits: they can be brutally toxic, they are often manufactured one p
- PRThree Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE BetIssued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP) A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tumors --- while carrying a market value that remains modest relative to many clinical-stage oncology peers. SAN FRANCISCO, June 08, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary -- Most clinical-stage cancer companies with three drugs that have reached human trials carry valuations in the hundreds of millions of dollars, or more. GT Biopharma, Inc. (NASDAQ:GTBP) has now advanced three TriKE® candidates into the clinic over time --- GTB-3550, GTB-3650 and GTB-5550 --- though its curr
- SECFate Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - FATE THERAPEUTICS INC (0001434316) (Filer)
- PRFate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual MeetingFT819 off-the-shelf CAR T-cell therapy product candidate continues to broaden patient access with 21 SLE patients now treated, including as outpatient administration in community hospitals Continued demonstration of rapid and sustained clinical improvement with favorable tolerability profile observed following treatment of systemic lupus erythematosus (SLE) patients with FT819 and less-intensive conditioning chemotherapy; a majority of evaluable patients on background glucocorticoids achieved either complete glucocorticoid discontinuation or guideline-based tapering targets FT819 demonstrated deep B-cell depletion with reconstitution of preferred less-differentiated state associated with a
- PRFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune diseases, today announced that on June 1, 2026, the Company granted restricted stock units (RSUs) representing 67,300 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees
- PRFate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual MeetingFT836 demonstrates meaningful reduction in target lesions without the use of conditioning chemotherapy in metastatic colorectal cancer Detection of FT836 in the peripheral blood and tumor tissue illustrates the unique ability to traffic to tumor site and functionally persist without the reliance on conditioning chemotherapy in allogeneic patient setting SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune diseases, presented clinical data this weeken
- PRThe $13 Million Company Teaching the Immune System to Hunt CancerIssued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP)Three drugs in human trials. A platform licensed from one of the world's top cancer-research universities. A market cap smaller than a Manhattan apartment. For investors willing to look where almost no one is looking, GT Biopharma is the kind of asymmetric setup that biotech is built on.NEW YORK, May 29, 2026 /CNW/ -- USA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ:GTBP) carried a market capitalization of roughly $13 million. Thirteen million. That is not a typo, and it is not a shell company. It is a clinical-stage immuno-oncology company with three sep
- INSIDEROfficer Tahl Cindy sold $48,084 worth of shares (25,590 units at $1.88), decreasing direct ownership by 4% to 628,155 units (SEC Form 4) (withholding obligation)4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
- INSIDERPresident and CEO Valamehr Bahram sold $54,482 worth of shares (28,946 units at $1.88), decreasing direct ownership by 4% to 635,762 units (SEC Form 4) to satisfy withholding tax4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
- PRFate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune DiseasesSAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that data from its off-the-shelf CAR T-cell programs will be featured at the American Society of Cancer Oncology Annual Meeting to be held in Chicago, IL, May 29 – June 2, 2026 and at the European Congress of Rheumatology being held in London, UK, June 3-6, 2026. Presentation details are as follows: ASCO – American Society of Cancer Oncology Product Candidate: FT836 Title: Prelim
- PRCell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative MarketsCell therapies and precision biologics are driving new opportunities across longevity, cognitive health, and neurological disease sectorsNEW YORK, May 20, 2026 /PRNewswire/ -- Market News Updates News Commentary - Cell-based therapies are quickly becoming one of the most talked-about areas in healthcare as researchers move beyond traditional drugs and focus on repairing and regenerating the body at the cellular level. Instead of only treating symptoms, scientists are now exploring ways to potentially reverse damage tied to aging and chronic disease. In the anti-aging space, stem cells, regenerative biologics, and senolytic therapies are being studied for their potential to restore tissue fun
- ANALYSTJefferies resumed coverage on Fate TherapeuticsJefferies resumed coverage of Fate Therapeutics with a rating of Buy
- PRThree TriKE Candidates In Clinic As NK Cell Engager Field ReorganizesEquity Insider News CommentaryIssued on behalf of GT Biopharma, Inc.Companies mentioned: GT Biopharma, Inc. (NASDAQ:GTBP), Fate Therapeutics, Inc. (NASDAQ:FATE), Nkarta, Inc. (NASDAQ:NKTX), ImmunityBio, Inc. (NASDAQ:IBRX), INmune Bio, Inc. (NASDAQ:INMB)SAN FRANCISCO, May 19, 2026 /CNW/ -- The case for natural killer cell-based immunotherapy has been one of the longer-running theses in clinical oncology. NK cells sit on the body's first line of defense against foreign invaders, can be deployed as off-the-shelf therapeutics derived from donor cells or pluripotent stem cells, and have demonstrated meaningfully lower rates of cytokine release syndrome and graft-versus-host disease than the autol
FATE FAQ
7 questionsWhat does Fate Therapeutics Inc. do?
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid...Where does FATE stock trade?
Fate Therapeutics Inc. (FATE) is listed on NASDAQ.What sector and industry is FATE in?
Fate Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Fate Therapeutics Inc. go public?
Fate Therapeutics Inc. (FATE) completed its IPO in 2013.What are analysts saying about FATE?
Fate Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Jefferies: Buy on 2026-05-19. Recent price targets range from $500.00 to $700.00.What companies are similar to FATE?
Notable peers in the same industry include TGTX (TG Therapeutics Inc.), TPTX (Turning Point Therapeutics Inc.), PSTX (Poseida Therapeutics Inc.), CDTX (Cidara Therapeutics Inc.). Compare FATE side-by-side with any of them on Quantisnow.How can I track FATE on Quantisnow?
Quantisnow aggregates Fate Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FATE to receive live email and push alerts on every new disclosure.